Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

Visualizar Toda a Documentação

D1500000

Diethylstilbestrol

European Pharmacopoeia (EP) Reference Standard

Sinônimo(s):

(E)-3,4-Bis(4-hydroxyphenyl)-3-hexene, DES, Stilbestrol

Faça loginpara ver os preços organizacionais e de contrato
Todas as fotos(1)

About This Item

Fórmula empírica (Notação de Hill):
C18H20O2
Número CAS:
56-53-1
Peso molecular:
268.35
Beilstein:
2056095
Número MDL:
MFCD00002373
Código UNSPSC:
41116107
ID de substância PubChem:
329798701
NACRES:
NA.24

grau

pharmaceutical primary standard

família API

diethylstilbestrol

fabricante/nome comercial

EDQM

aplicação(ões)

pharmaceutical (small molecule)

Formato

neat

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

CC\C(c1ccc(O)cc1)=C(\CC)c2ccc(O)cc2

InChI

1S/C18H20O2/c1-3-17(13-5-9-15(19)10-6-13)18(4-2)14-7-11-16(20)12-8-14/h5-12,19-20H,3-4H2,1-2H3/b18-17+

chave InChI

RGLYKWWBQGJZGM-ISLYRVAYSA-N

Informações sobre genes

human ... ESR1(2099)

Procurando produtos similares? Visita Guia de comparação de produtos

Descrição geral

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Aplicação

Diethylstilbestrol EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Embalagem

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Outras notas

Sales restrictions may apply.

Palavra indicadora

Danger

Classificações de perigo

Aquatic Acute 1 - Aquatic Chronic 1 - Carc. 1B - Eye Irrit. 2 - Repr. 1B - Skin Irrit. 2 - STOT SE 3

Órgãos-alvo

Respiratory system

Código de classe de armazenamento

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de risco de água (WGK)

WGK 3

Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documentos section.

Se precisar de ajuda, entre em contato Atendimento ao cliente

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Shuji Yamashita
Current pharmaceutical design, 12(12), 1505-1520 (2006-04-14)
Neonatal diethylstilbestrol (DES) exposure elicits a wide range of abnormalities in the female mouse genital tract. This animal model system is suitable for investigating the mechanism of DES syndrome in humans. Accumulated evidence has shown that critical periods in development
Yuliya Dobrydneva et al.
Journal of cardiovascular pharmacology, 55(5), 522-530 (2010-02-12)
Compounds with the stilbene pharmacophore and other nonsteroidal estrogens have previously been shown to inhibit thrombin-induced elevation of intracellular free calcium ([Ca]i) in human platelets. Thrombin elevates [Ca]i in platelets predominantly by activating a store-operated Ca entry (SOCE) mechanism, probably
S B Malkowicz
Urology, 58(2 Suppl 1), 108-113 (2001-08-15)
Diethylstilbestrol administration was a classic form of androgen deprivation therapy (ADT) that gradually fell out of favor because of its cardiovascular toxicity, economic disinterest on the part of manufacturers, and the emergence of novel therapeutic agents with a superior safety
Pierre-Olivier Bosset et al.
BJU international, 110(11 Pt C), E826-E829 (2012-05-15)
What's known on the subject? and What does the study add? Diethylstilbestrol (DES) has been found to have anti-tumour properties and clinical effectiveness in prostate cancer that is resistant to the first-line hormonal therapy. This review found that low-dose DES
Douglas S Scherr et al.
The Journal of urology, 170(5), 1703-1708 (2003-10-09)
During the last 2 decades there has been an increase in the number of men with prostate cancer placed on luteinizing hormone releasing hormone (LH-RH) agonist therapy. In addition, the duration of individual therapy has extended from what was once
Exibir todos os documentos relacionados

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica